- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 10,545
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Cancer Stage II, Colorectal Cancer Stage III
- Interventions
- Regular blood sample collection for ctDNA assessment
- Procedure
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,079 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 17
- States / cities
- California City, California • Concord, California • Greenbrae, California + 14 more
- Conditions
- Asthma
- Interventions
- Symbicort pMDI, Budesonide pMDI
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 882 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 59
- States / cities
- Hoover, Alabama • Montgomery, Alabama • Gilbert, Arizona + 56 more
- Conditions
- Endometrial Cancer
- Interventions
- Trastuzumab Deruxtecan, Chemotherapy
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 710 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 14
- States / cities
- Fort Lauderdale, Florida • Miami, Florida • Miami Beach, Florida + 10 more
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Omacetaxine mepesuccinate
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Atlanta, Georgia • Indianapolis, Indiana + 3 more
- Conditions
- Cerebrospinal Fluid Leak
- Interventions
- EVICEL Fibrin Sealant, Hydrogel sealant
- Biological · Device
- Lead sponsor
- Ethicon, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • Jacksonville, Florida + 10 more
- Conditions
- HNSCC
- Interventions
- Danvatirsen, Pembrolizumab
- Drug
- Lead sponsor
- Flamingo Therapeutics NV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • Irvine, California • Torrance, California + 17 more
- Conditions
- Hodgkin Disease
- Interventions
- Brentuximab vedotin, Doxorubicin, Vinblastine, Dacarbazine
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Cincinnati, Ohio
- Conditions
- Pancreatic Cancer Metastatic
- Interventions
- CPI 613, mFolfirinox, Folfirinox
- Drug
- Lead sponsor
- Cornerstone Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 40
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Duarte, California + 35 more
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Placebo (for alirocumab), Ezetimibe, Placebo (for ezetimibe), Lipid Modifying Therapy (LMT)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
- Conditions
- Hypercholesterolemia
- Interventions
- CIVI 007
- Drug
- Lead sponsor
- Civi Biopharma, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 7
- States / cities
- Jacksonville, Florida • Port Orange, Florida • Indianapolis, Indiana + 4 more
- Conditions
- Hemophilia A
- Interventions
- FVIII concentrate
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 13
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Lexington, Kentucky + 9 more
- Conditions
- Aortic Valve Insufficiency, Aortic Valve Stenosis
- Interventions
- SAPIEN X4/X4S THV
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2039
- U.S. locations
- 34
- States / cities
- Newport Beach, California • San Francisco, California • Stanford, California + 26 more
- Conditions
- Liver Neoplasms
- Interventions
- Regorafenib (Stivarga, BAY73-4506)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,010 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 17
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Gainesville, Florida + 13 more
- Conditions
- Rhinitis
- Interventions
- montelukast, placebo
- Drug
- Lead sponsor
- Bernstein, Jonathan A., M.D.
- Individual
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- P-BCMA-ALLO1 CAR-T cells, Rimiducid, Methotrexate
- Biological · Drug
- Lead sponsor
- Poseida Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2042
- U.S. locations
- 23
- States / cities
- Goodyear, Arizona • San Diego, California • San Francisco, California + 19 more
- Conditions
- Arrhythmia, Tachycardia, Atrial Fibrillation, Ventricular Fibrillation
- Interventions
- Remote Management, In-Office Care
- Other
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,009 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 127
- States / cities
- Mobile, Alabama • Mesa, Arizona • Scottsdale, Arizona + 124 more
- Conditions
- Tuberous Sclerosis Complex-associated Refractory Seizures
- Interventions
- RAD001, Placebo, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
- Conditions
- Primary Open Angle Glaucoma
- Interventions
- Not listed
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 26
- States / cities
- Beverly Hills, California • Petaluma, California • Sacramento, California + 23 more
- Conditions
- Cardiac Arrhythmias
- Interventions
- Rhythmia mapping system, IntellaMap Orion mapping catheter
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 577 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Orange, California • Torrance, California + 14 more
- Conditions
- Endometriosis, Endometriosis-related Pain, Endometriosis Pelvic, Endometriosis; Peritoneum
- Interventions
- Diathermy, CO2 Laser, Argon Beam Coagulator
- Device
- Lead sponsor
- TriHealth Inc.
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Aortic Dissection
- Interventions
- Endovascular Treatment (Zenith)
- Device
- Lead sponsor
- Cook Research Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Gainesville, Florida • Tampa, Florida + 18 more
- Conditions
- Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
- Interventions
- Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 25
- States / cities
- La Jolla, California • Miami, Florida • Tampa, Florida + 20 more
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo matching Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 2,245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 155
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 117 more